Last updated: February 13, 2026
Overview of the Drug
NDC 00527-1318 is marketed as Xyrem (sodium oxybate), approved by the FDA for narcolepsy with cataplexy and, in some cases, for treatment-resistant depression. It is a Schedule III controlled substance due to its sedative effects, and its formulation is typically in a liquid form.
Market Size and Dynamics
Market Penetration: Xyrem primarily targets narcolepsy patients, estimated at approximately 200,000 individuals in the U.S. (National Sleep Foundation). Of these, roughly 75% receive pharmacotherapy, many on Xyrem, accounting for an estimated patient base of 150,000 in the U.S.
Global Reach: The drug is marketed in over 30 countries, but U.S. sales dominate. International markets are growing, driven by increasing awareness and diagnostic rates.
Competitive Landscape: The main competitors include pitolisant (Wakix), solriamfetol (Jorrido), and off-label use of stimulants, but no direct product rivals Xyrem’s unique efficacy in narcolepsy with cataplexy.
Revenue Data: In FY2022, Jazz Pharmaceuticals (the manufacturer) reported Xyrem revenue at approximately $792 million, with a growth rate of 4% year-over-year, reflecting sustained demand.
Pricing Overview
Current U.S. Pricing: The Wholesale Acquisition Cost (WAC) for Xyrem averages $1,230 per 30 mL bottle (approximately 60 mL/day for a month). The average wholesale price (AWP) is around $1,350 for a 30 mL bottle.
Reimbursement: Medicare and insurance typically reimburse close to the AWP, but patient copays vary based on insurance plans.
Pricing Benchmarks: Comparing to similar Schedule III drugs, Xyrem maintains a premium due to its efficacy, safety profile, and limited competition.
Cost and Price Projections
Factors Influencing Future Pricing:
- Patent and Patent Exclusivity: Xyrem’s core patent expired in 2018, but new formulations or delivery systems may extend exclusivity.
- Regulatory Environment: Increased scrutiny over controlled substances may impact supply chain costs and pricing.
- Reimbursement Trends: Payers’ willingness to reimburse at current rates influences price stability.
- International Licensing and Market Expansion: Entry into emerging markets might reduce price levels due to cost sensitivities.
Projected Pricing Trends:
- Short-term (1-2 years): Prices are expected to remain stable or slightly increase (2-3%) driven by inflation and supply costs.
- Mid-term (3-5 years): Potential for a 5-7% decrease if new competitors or formulations enter the market and patent exclusivity considerations change.
- Long-term (5+ years): Prices may decline further, possibly 10-15%, as biosimilars or alternative therapies emerge, barring new indications or formulations that extend exclusivity.
Market Entry and Impact of Biosimilars
Currently, no biosimilar or generic versions are approved or available for sodium oxybate, preventing significant price erosion. However, patent cliffs and regulatory pathways could alter this landscape.
Emerging Trends and Considerations
- Alternative Delivery Methods: Oral formulations with improved stability or adherence could affect market pricing.
- Expanded Indications: Approval for additional conditions, such as alcohol dependence, could increase sales volume, impacting average prices through market expansion.
- Policy Changes: Changes in controlled substance regulation or drug pricing policies could influence the drug’s market dynamics.
Summary
| Parameter |
Current Status |
Outlook |
| U.S. Market Size |
~150,000 patients |
Stable, with minor growth |
| Revenue (FY2022) |
~$792 million |
Slight growth expected |
| Price (per 30 mL bottle) |
~$1,230 WAC, ~$1,350 AWP |
Stable short-term; potential slight decline mid-term |
| Competition |
Limited, no biosimilars/generics |
Potential future entry |
| Patent Status |
Expired (2018), potential for new formulations |
Could extend exclusivity |
Key Takeaways
- The Xyrem market remains robust, supported by specialized indications and limited competition.
- Prices are expected to remain largely stable in the near term, with gradual declines possible as biosimilars or generics could enter the market.
- Market expansion into other indications and international markets offers growth opportunities without significant price erosion.
- Regulatory and patent developments will be critical in shaping future price trajectories.
FAQs
-
What are the main factors influencing Xyrem pricing?
Regulatory changes, patent status, market competition, reimbursement policies, and manufacturing costs.
-
When might biosimilars or generics impact Xyrem’s market?
Potentially within 5-7 years, depending on patent litigation outcomes and regulatory approvals.
-
How does international expansion affect pricing?
Market entry into emerging markets often leads to lower prices due to price sensitivity and local regulatory standards.
-
Are there new formulations in development?
No publicly announced formulations that extend exclusivity, but research into alternative delivery systems continues.
-
What is the outlook for Xyrem’s revenue growth?
Moderate growth driven by expanding indications and geographic markets, barring significant policy or competitive disruptions.
References
[1] National Sleep Foundation. "Narcolepsy Fact Sheet," 2022.
[2] Jazz Pharmaceuticals FY2022 Annual Report.
[3] U.S. Food and Drug Administration. Drug Approvals and Patent Data, 2018.
